# Verastem share price today (Verastem, Inc., VSTM)

> Verastem, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. VSTM · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/vstm

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $9.38 (+16.2% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026): ₹0.0 B
- ROE: −366%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Verastem share price today? Verastem, Inc.'s share price was $9.38 at the close on 5 November 2026. That is 50.6% above its average price over the last 200 trading days. In the last 52 weeks it traded between $4 and $11, and at that close it sat 82% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 14 weeks in a row. Over the last 1 year the share price moved +100% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Verastem pay? Verastem, Inc. pays no dividend. In the last 10 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Verastem on? Verastem is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Verastem profitable? Verastem, Inc. posted a net loss of ₹0.03 B in the Jun 2026 quarter. The full FY25 year was a loss of ₹0.2 B. That loss is 86.5% of the quarter's revenue. The same quarter a year earlier lost ₹0.03 B. 10 of the last 10 reported quarters were loss-making. Jun 2026 profit was ₹0.0 B. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Verastem make, and is it growing? Verastem, Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, +1,775.4% on the same quarter a year earlier. Over 4 years it has grown 97.0% a year on average. The last full year, FY25, came in at ₹0.0 B. The last four reported quarters add to ₹0.1 B. FY25 revenue was ₹0.0 B, +209.1% on the year before. Recent pace: the last four quarters grew +1,775.4% on average, against 97.0% a year over the longer run, so this year is growing faster than its own long-run rate. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Verastem keep? Verastem, Inc. has almost no sales yet: FY25 revenue was ₹0.0 B. On sales that small an operating margin is not a useful reading, so this section is left out until sales grow. ## Is Verastem's profit turning into cash? Verastem, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.1 B of cash, against −₹0.2 B of profit. After null of spending on assets, free cash was −₹0.1 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Verastem's cash go? Verastem, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 2 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 2 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Verastem's P/E ratio, and how does it compare with its own history? Verastem, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Verastem business getting better or worse? Verastem, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 4 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Verastem earn on its capital? Verastem, Inc. earned a ROE of −366% in FY25. Its return on capital used (ROIC) is left out: on sales this small it reads −114%, a number that says nothing useful about the business. ## Does Verastem have too much debt? Verastem, Inc. has total debt of ₹0.1 B against shareholder equity of ₹0.0 B as of Jun 2026, so its debt is 1.69× its equity. Year by year, that ratio went from 0.04 in FY21 to 1.52 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Verastem shareholding pattern? 16.1% of Verastem, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 3.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Verastem from balance-sheet trouble? For Verastem, Inc., the Z-score is −8.03. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −8.03 is inside the danger zone, so the balance sheet is a real risk. ## How does Verastem rank in its industry? There is no score against its industry: Verastem, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Verastem compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Verastem in size? Verastem is the 106th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: MannKind Corporation, Silence Therapeutics plc and Inhibrx Biosciences, Inc. Just below it: Janux Therapeutics, Inc., Rigel Pharmaceuticals, Inc. and Immatics N.V. ### Biotechnology companies close in size

1. [MannKind Corporation](https://www.sectoralpha.in/us/stocks/mnkd) $1.2 billion
2. [Silence Therapeutics plc](https://www.sectoralpha.in/us/stocks/sln) $1.2 billion
3. [Inhibrx Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/inbx) $1.2 billion
4. Verastem, Inc. $1.1 billion
5. [Janux Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/janx) $1.1 billion
6. [Rigel Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/rigl) $958 million
7. [Immatics N.V.](https://www.sectoralpha.in/us/stocks/imtx) $945 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [D-Market Elektronik Hizmetler ve Ticaret A.S.](https://www.sectoralpha.in/us/stocks/heps) $1.2 billion · Internet Retail
2. [Metropolitan Bank Holding Corp.](https://www.sectoralpha.in/us/stocks/mcb) $1.2 billion · Banks - Regional
3. Verastem, Inc. $1.2 billion
4. [Yelp Inc.](https://www.sectoralpha.in/us/stocks/yelp) $1.2 billion · Internet Content & Information
5. [Tripadvisor, Inc.](https://www.sectoralpha.in/us/stocks/trip) $1.2 billion · Travel Services

## What else do people ask about Verastem? ### What were Verastem's latest quarterly results? Verastem, Inc. reported revenue of ₹0.0 B and a net loss of ₹0.0 B for the Jun 2026 quarter. The operating margin was −81.6%, 1,966.3 percentage points higher than a year earlier (as of 5 November 2026). ### What is Verastem's profit? Verastem, Inc. earned ₹0.0 B of net profit in the Jun 2026 quarter. Full-year FY25 profit was −₹0.2 B. The operating margin was −81.6% in the latest quarter (as of 5 November 2026). ### What is Verastem's market cap? Verastem, Inc.'s market capitalisation is $1.1 B at a stock price of $9.38. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Verastem performing? Verastem, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 14 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will Verastem's stock price go up? This page does not forecast Verastem, Inc.'s stock price. What it shows instead: the stock price is $9.38. Nobody can reliably say which way a price will move, and this site does not try (as of 5 November 2026). ### Does Verastem have too much debt? Yes, Verastem, Inc. has a lot of debt: its debt is 12.73× its equity. A year-by-year history of its borrowings is not in our data, so this uses the latest reading. Keep that borrowing in mind when reading the returns on this page (as of 5 November 2026). ### What could break the Verastem story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Verastem a stock worth studying right now? What the numbers show: Verastem, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.